From 2nd of June we are suspending coverage of companies below due to a reallocation of resources. Our prior estimates should no longer be used as an indicator for the company moving forward.ADIDASBEIERSDORFCARREFOURDELIVERY HEROESSILORLUXOTTICAHELLOFRESHHermès InternationalHUGO BOSSINTERPARFUMSJUS
Q1 disappointed because of delayed deliveries in the US (customs slowdowns) and at Cuir Center (dockworker strikes), only pointing to a catch-up in coming months. Price adjustments have already been implemented to cope with tariffs and FX and we expect quantified EBITDA guidance alongside the H1 pu
Post-FY 2024, we have cut our estimates by 2% and our PT from EUR47 to EUR46. We see 2025 as a year of recovery for both revenues (set to rise >5%) and EBITDA (up 17% YoY) with consensus slightly conservative. The investment case remains untouched with MSD% sales CAGR, a margin accretive focus o
MONT-SAINT-GUIBERT, Belgique--(BUSINESS WIRE)-- Regulatory News: Celyad Oncology (Euronext: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (la “Société”), annonce aujourd'hui la publication des données précliniques du candidat allogénique sans édition de génome CYAD-211 et des données cliniques de l'étude clinique de phase I IMMUNICY-1 qui a évalué CYAD-211 chez des patients atteints de myélome multiple (MM) récidivant ou réfractaire (r/r). Les résultats ont été publiés dans l'International Journal of Molecular Science (IJMS). CYAD-211 est le premier candidat à base de lymphocytes T à réce...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.